Search results
Author(s):
Joanna M Bilak
,
Uazman Alam
,
Christopher A Miller
,
et al
Added:
1 year ago
Author(s):
Sunil K Nadar
,
Muhammad Mujtaba Shaikh
Added:
3 years ago
Dear Editor,
We would like to thank García-Escobar and Ingelmo for their letter regarding our article on the use of biomarkers in routine clinical care for heart failure.1,2 It was with interest that we read their comments on the use of red cell volume distribution width (RDW) as another biomarker for use in the management of patients with heart failure. As mentioned in their letter, RDW is a…
View more
Author(s):
Ovidiu Chioncel
,
Sean P Collins
,
Stephen J Greene
,
et al
Added:
3 years ago
Hospitalisation is a critical event in the clinical course of heart failure (HF) and despite relatively rapid relief of symptoms, hospitalisation is followed by an increased risk of death and re-hospitalisation.1 While performance measures have been developed in the last few years with the intent of improving post-discharge outcomes, post-discharge mortality rates remain unchanged or have…
View more
Author(s):
Sunil K Nadar
,
Muhammad Mujtaba Shaikh
Added:
3 years ago
The National Institutes of Health Biomarkers Definitions Working Group define a biomarker as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”.1 Biomarkers have become increasingly important in current medical practice as they offer an easy way to either…
View more
Author(s):
John GF Cleland
Added:
10 months ago
ESC-HFA 2023 – Prof John Cleland (University of Glasgow, Glasgow, UK) discusses the findings from a study that looked at the diagnostic of heart failure in a cohort of 1.1 million people using the NHS EMR database.
Finding presented at Heart Failure 2023, showed that more people treated with LD than receive diagnosis of heart failure, this disparity was greater in women compared to men.
…
View more
Author(s):
Yury Lopatin
Added:
3 years ago
In 2016, the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC)1 introduced heart failure (HF) with mid-range ejection fraction (HFmrEF) as a distinct phenotype. This distinction was expected to stimulate research on the underlying characteristics, pathophysiology and treatment of patients with HFmrEF. Indeed, in the following…
View more
Michael Weber
Job title: Professor of Medicine
Author
John Eikelboom
Job title: Associate Professor
Author
Michael Fu
Research Area(s) / Expertise:
Job title: Professor, Principal Investigator, Senior Consultant Physician/Cardiologist
Author
Author(s):
Davide Margonato
,
Simone Mazzetti
,
Renata De Maria
,
et al
Added:
3 years ago
Heart failure (HF) is a complex syndrome caused by functional and structural abnormalities of the left ventricle (LV) resulting in a combination of typical signs and symptoms. Historically, HF has been classified according to LV ejection fraction (EF) as either HF with reduced EF (HFrEF; LVEF <40%) or HF with preserved EF (HFpEF; LVEF >50%).1,2 The 2016 European Society of Cardiology (ESC)…
View more